Pharmacological properties of mangiferin: bioavailability, mechanisms of action and clinical perspectives
Authors:
- Jelena ZivkovićJelena Zivković
- Kammala Ananth KumarKKKammala Ananth Kumar
- Rapuru RushendranRRRapuru Rushendran
- Kaliappan IlangoKIKaliappan Ilango
- Nouran M. FahmyNFNouran M. Fahmy
- Heba A. S. El-NasharHEHeba A. S. El-Nashar
- Mohamed El-ShazlyMohamed El-Shazly
- Shahira M. EzzatSEShahira M. Ezzat
- Guiomar Melgar-LalanneGMGuiomar Melgar-Lalanne
- Alejandra Romero-MonteroARAlejandra Romero-Montero
- Sheila I. Peña-CoronaSPSheila I. Peña-Corona
- Gerardo Leyva-GomezGerardo Leyva-Gomez
- 1 September 2023
- journal article
- review article
- Published by Springer Nature in Naunyn-Schmiedeberg's Archives of Pharmacology
- Vol. 397 (2) , 763-781
Abstract
This review aims to provide an in-depth analysis of the pharmacological properties of mangiferin, focusing primarily on its bioavailability and mechanisms of action, and its potential therapeutic applications, especially in the context of chronic diseases. We conducted a comprehensive examination of in vitro and in vivo studies, as well as clinical trials involving mangiferin or plant extracts containing mangiferin. The primary source of mangiferin is Mangifera indica, but it’s also found in other plant species from the families Anacardiaceae, Gentianaceae, and Iridaceae. Mangiferin has exhibited a myriad of therapeutic properties, presenting itself as a promising candidate for treating various chronic conditions including neurodegenerative disorders, cardiovascular diseases, renal and pulmonary diseases, diabetes, and obesity. Despite the promising results showcased in many in vitro studies and certain animal studies, the application of mangiferin has been limited due to its poor solubility, absorption, and overall bioavailability. Mangiferin offers significant therapeutic potential in treating a spectrum of chronic diseases, as evidenced by both in vitro and clinical trials. However, the challenges concerning its bioavailability necessitate further research, particularly in optimizing its delivery and absorption, to harness its full medicinal potential. This review serves as a comprehensive update on the health-promoting and therapeutic activities of mangiferin.Keywords
This publication has 109 references indexed in Scilit:
- Mangiferin mitigates diabetic cardiomyopathy in streptozotocin-diabetic ratsCanadian Journal of Physiology and Pharmacology, 2013
- Polyphenolic and Vitamin C Contents and Antioxidant Activities of Aqueous Extracts from Mature-Green and Ripe Fruit Fleshes of Mangifera sp.Journal of Agricultural and Food Chemistry, 2012
- Mangiferin Decreases Plasma Free Fatty Acids through Promoting Its Catabolism in Liver by Activation of AMPKPLOS ONE, 2012
- A call for using natural compounds in the development of new antimalarial treatments – an introductionMalaria Journal, 2011
- Acute Toxicity, Antidepressive and Mao Inhibitory Activity of Mangiferin Isolated fromHypericum AucheriBiotechnology & Biotechnological Equipment, 2011
- Determination of Mangiferin in Rat Eyes and Pharmacokinetic Study in Plasma After Oral Administration of Mangiferin-Hydroxypropyl-Beta-Cyclodextrin InclusionJournal of Ocular Pharmacology and Therapeutics, 2010
- Myanmar mango landraces reveal genetic uniqueness over common cultivars from Florida, India, and Southeast AsiaGenome, 2010
- Characterization of the mangiferin–human serum albumin complex by spectroscopic and molecular modeling approachesJournal of Pharmaceutical and Biomedical Analysis, 2009
- Antihyperglycemic Effect of Mangiferin in Streptozotocin Induced Diabetic RatsJournal of Health Science, 2009
- Capillary electrophoresis analysis of mangiferin extracted from Mangifera indica L. bark and Mangifera persiciformis C.Y. Wu et T.L. Ming leavesJournal of Chromatography B, 2005